Filtered By:
Vaccination: Cancer Vaccines
Countries: Israel Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
Oncologist. 2023 Feb 28:oyad003. doi: 10.1093/oncolo/oyad003. Online ahead of print.ABSTRACTSince January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BN...
Source: The Oncologist - March 1, 2023 Category: Cancer & Oncology Authors: Idan Cohen Salvatore Campisi-Pfinto Orit Rozenberg Raul Colodner Gil Bar-Sela Source Type: research
Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience
CONCLUSIONS: The incidence of IIM increased during the COVID-19 pandemic. These patients display unique features and a more severe presentation. Fortunately, the prognosis remains unchanged.PMID:36826786 | DOI:10.55563/clinexprheumatol/970881
Source: Cancer Control - February 24, 2023 Category: Cancer & Oncology Authors: Fadi Kharouf Ariel Kenig Emilie Bohbot Limor Rubin Hagit Peleg Oded Shamriz Source Type: research
Risk of Inappropriately Timed Live Vaccination After Pediatric Cardiovascular Surgery
CONCLUSIONS: Infants who undergo cardiac surgery between the ages of 5 and 12 months are at risk for inappropriate live vaccination timing. A clinically significant percentage of pediatric patients who received blood products during a cardiac surgical admission later received live vaccines at times that were inconsistent with AAP, ACIP, and CDC recommendations. Future interventions aimed at educating providers and patients may be warranted.PMID:36415771 | PMC:PMC9674358 | DOI:10.5863/1551-6776-27.8.750
Source: Cancer Control - November 23, 2022 Category: Cancer & Oncology Authors: Abigail N Shockley Emily N Israel Christopher A Thomas Source Type: research
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data
CONCLUSION: Serum IgG anti-S. sonnei LPS threshold levels can predict degrees of vaccine efficacy and be used for the evaluation of new vaccine candidates.PMID:36243351 | DOI:10.1016/j.cmi.2022.10.011
Source: Cancer Control - October 15, 2022 Category: Cancer & Oncology Authors: Dani Cohen Shai Ashkenazi Rachel Schneerson Nahid Farzam Anya Bialik Shiri Meron-Sudai Valeria Asato Sophy Goren Tomer Ziv Baran Khitam Muhsen Peter B Gilbert Calman A MacLennan Source Type: research
The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada
Healthc Policy. 2022 Feb;17(3):81-90. doi: 10.12927/hcpol.2022.26726.ABSTRACTRegulatory and reimbursement decisions for drugs and vaccines are increasingly based on limited safety and efficacy evidence. In this environment, life-cycle approaches to evaluation are needed. A life-cycle approach grants market approval and/or positive reimbursement decisions based on an undertaking to conduct post-market clinical trials that address evidentiary uncertainties, relying on the collection and analysis of post-market data. In practice, however, both conditional regulatory and reimbursement decisions have proven problematic. Here we...
Source: Cancer Control - March 23, 2022 Category: Cancer & Oncology Authors: Melanie McPhail Christopher McCabe Dean A Regier Tania Bubela Source Type: research
What to Know About a Fourth COVID-19 Vaccine Dose
Most people ages 12 and older are considered “up to date” with their COVID-19 vaccines if they received either three doses of the mRNA shots from Pfizer-BioNTech or Moderna, or two doses of Johnson & Johnson’s Janssen vaccine. But some public health experts say another dose might be needed in the coming months.
The Washington Post reports today that Pfizer and BioNTech soon plan to request authorization from the U.S. Food and Drug Administration (FDA) for a fourth dose of their vaccine in people ages 65 and older. In the past few days, Albert Bourla, Pfizer’s CEO, has said that he believes every...
Source: TIME: Health - March 15, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
When and How Would You Screen This Patient for Cervical Cancer? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2022 Feb 8. doi: 10.7326/M21-4372. Online ahead of print.ABSTRACTSuccessful screening programs based on cervical cytology have dramatically reduced the incidence of cervical cancer in the United States. Human papillomavirus immunization is poised to reduce it further as an increasing percentage of vaccinated women reach adulthood. A recent guideline from the American Cancer Society advises that cervical cancer screening begin at age 25 and that high-risk human papillomavirus testing is the preferred screening test. The U.S. Preventive Services Task Force recommends screening begin at age 21 and that cytolog...
Source: Annals of Internal Medicine - February 7, 2022 Category: Internal Medicine Authors: Eileen E Reynolds Amy Weinstein Huma Farid Howard Libman Source Type: research
